Skip to main content
Premium Trial:

Request an Annual Quote

PPO Stratose to Cover Paradigm's PCDx Cancer Test

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm today said that it and preferred provider organization Stratose have entered into a contract to cover the PCDx test. 

Stratose, based in Atlanta, has more than 850,000 direct and affiliate contracts with providers nationwide. Stratose's members will now have access to the PCDx next-generation sequencing-based test, which identifies the underlying genomic and proteomic mutations in a patient's tumor DNA, RNA, and proteins. 

Paradigm was spun out of the International Genomics Consortium and the University of Michigan in 2012. The PCDx test interrogates relevant genomic targets at more than 5,000X average depth of coverage with test results deliverable in four to five business days. 

"Through this contract, millions of Stratose client members and their treating clinicians will have access to this important oncology service and make possible more informed and individually tailored treatment strategies," Paradigm CEO Robert Penny said in a statement.